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OBJECTIVES: Acute retinal necrosis is a rapidly progressive and devastating viral retinitis caused by the herpesvirus
family. Systemic acyclovir is the treatment of choice; however, the progression of retinal lesions ceases
approximately 2 days after treatment initiation. An intravitreal injection of acyclovir may be used an adjuvant
therapy during the first 2 days of treatment when systemically administered acyclovir has not reached therapeutic
levels in the retina. The aims of this study were to determine the pharmacokinetic profile of acyclovir in the rabbit
vitreous after intravitreal injection and the functional effects of acyclovir in the rabbit retina.
METHODS: Acyclovir (Acyclovir; Bedford Laboratories, Bedford, OH, USA) 1 mg in 0.1 mL was injected into the right
eye vitreous of 32 New Zealand white rabbits, and 0.1 mL sterile saline solution was injected into the left eye as a
control. The animals were sacrificed after 2, 9, 14, or 28 days. The eyes were enucleated, and the vitreous was
removed. The half-life of acyclovir was determined using high-performance liquid chromatography.
Electroretinograms were recorded on days 2, 9, 14, and 28 in the eight animals that were sacrificed 28 days after
injection according to a modified protocol of the International Society for Clinical Electrophysiology of Vision.
RESULTS: Acyclovir rapidly decayed in the vitreous within the first two days after treatment and remained at low
levels from day 9 onward. The eyes that were injected with acyclovir did not present any electroretinographic
changes compared with the control eyes.
CONCLUSIONS: The vitreous half-life of acyclovir is short, and the electrophysiological findings suggest that the
intravitreal delivery of 1 mg acyclovir is safe and well tolerated by the rabbit retina.
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INTRODUCTION
Acute retinal necrosis (ARN) is a rapidly progressive viral
retinitis that is caused by members of the herpesvirus family
and has an unfavorable visual prognosis (1,2). Prompt
recognition of ARN is important, and patients who are
treated early with high doses of intravenous acyclovir have
a better visual outcome and a lower incidence of retinal
detachment (3).
Acyclovir is a potent systemic antiviral that has been the
drug of choice for the treatment of ARN because of its
selectivity against the herpes simplex virus and the
varicella-zoster virus (4,5). The goal of treatment is to stop
the progression of retinal lesions. Clinically, the progression
of existing retinal lesions usually ceases approximately 2
days after the initiation of treatment with intravenous
acyclovir, and visible regression may be observed after
approximately 4 days (1). Complete regression occurs after
an average of 32.5 days when the retina may have already
been irreversibly damaged (1).
To penetrate the eye, drugs must overcome the blood-
ocular barrier, which greatly decreases their bioavailability
to the retina (6). Intravitreal injections bypass the blood-
retinal barrier and thus provide immediate drug delivery at
therapeutic levels directly to the target site.
There is evidence that the time between diagnosis and the
initiation of treatment may be a prognostic factor and that
the reduction of this interval may improve the outcome of
ARN (7). We postulate that the intravitreal injection of
acyclovir as soon as the diagnosis of ARN has been estab-
lished may be a potential adjuvant therapy because it may
help to control this type of aggressive retinitis within the
crucial first 48 hours, when systemic acyclovir has not
reached therapeutic levels in the retina.
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In this study, we investigated the pharmacokinetic profile
and functional effects of acyclovir in the rabbit vitreous and
the retina, respectively, at different time points after an
intravitreal injection.
METHODS
Animals
In total, 32 New Zealand white rabbits (weight, 2.0-2.5 kg)
were included in this study. The animals were treated
according to the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthal-
mic and Vision Research. The experiments were approved by
the Research Ethics Committee of the Universidade de Sa˜o
Paulo, Faculdade de Medicina and by the Committee for
Ethics in Animal Research of the Instituto de Psicologia at the
Universidade de Sa˜o Paulo (Sa˜o Paulo, Brazil).
The animals were housed in individual cages under a 12/
12-hour light-dark cycle with free access to water and food.
Before every procedure (intravitreal injection, ERG, and
sacrifice), the animals were anesthetized with an intramus-
cular injection of 50 mg/kg ketamine hydrochloride (Keta-
mina; Agener, Sa˜o Paulo, Brazil) and 6.7 mg/kg xylazine
hydrochloride (Calmiun; Agener, Sa˜o Paulo, Brazil). The
pupils were dilated with topical 0.5% tropicamide
(Mydriacyl; Alcon, Sa˜o Paulo, Brazil), and the eyes were
anesthetized with 0.5% proxymetacaine hydrochloride
(Anestalcon; Alcon, Sa˜o Paulo, Brazil). A slit-lamp examina-
tion and indirect fundus ophthalmoscopy were performed in
all of the eyes prior to the intravitreal injections and after 2, 9,
14, and 28 days to detect signs of inflammation or infection.
All of the animals were sacrificed with an intravenous
injection of 70 mg/kg sodium pentobarbital (Euthanyle;
Brouwer, Buenos Ayres, Argentina) under deep anesthesia.
Acyclovir preparation
The original solution of acyclovir (Acyclovir; Bedford
Laboratories, Bedford, OH) was diluted with sterile saline
solution (saline) to reach a concentration of 10 mg/mL for
injection, and 0.1 mL (1 mg) was injected directly into the
vitreous.
Intravitreal injection
Before the injections, anterior chamber paracentesis
(0.1 mL of the aqueous humor) was performed with a 27-
gauge needle to prevent an increase in intraocular pressure
and minimize drug reflux. The intravitreal injections were
performed using a 30-gauge needle that was attached to a 1-
mL tuberculin syringe, which was inserted approximately
3 mm posterior to the limbus, and 0.1 mL acyclovir was
slowly injected directly into the vitreous. The right eye of
each rabbit was injected with the acyclovir solution and the
left eye was injected with saline as a control.
High-performance liquid chromatography for
vitreous half-life determination
To determine the half-life of acyclovir in the vitreous, the
animals were divided into four groups of eight animals each.
All the animals received an intravitreal injection of 1 mg/
0.1 mL acyclovir in the right eye and 0.1 mL saline in the left
eye. The animals were sacrificed on days 2, 9, 14, and 28 after
intravitreal injection. The eyes were enucleated, the anterior
segment and lens were discarded, and the vitreous body was
removed and frozen at -18 C˚ for a high-performance liquid
chromatography (HPLC) assay. Peripheral blood was drawn
at the time of sacrifice to determine the systemic concentra-
tion of acyclovir after intravitreal injection. The samples were
frozen at -18 C˚ for HPLC.
HPLC for the determination of vitreous and systemic
acyclovir levels has been previously described (8-11).
Briefly, the chromatographic system consisted of a Merck-
Hitachi LaChrom Elite apparatus that was equipped with
an autosampler with a sample loop of 100 mL (model L-
2200, Merck-Hitachi, Germany), a pump with a constant
flow rate of 1.4 mL/min (model L-2130, Merck-Hitachi,
Germany), and a diode array detector with a wavelength
of 215 nm (model L-2450; Merck-Hitachi, Germany). Sepa-
ration chromatography was performed using an Ace 5
C18 column (25064.6 mm id, Advanced Chromatography
Technologies, Scotland) that was maintained at 50 C˚
(column oven model L-2300, Merck-Hitachi, Germany). A
mixture of acetonitrile (Merck, Darmstadt, Germany) and
40 mM phosphoric acid buffer (Omega, Belo Horizonte,
Brazil) at pH 3.0 (32:68 v/v) was used as the mobile phase.
Under these experimental conditions, the retention time
was 14.0 min.
Sample treatment: Frozen vitreous samples were thawed
at ambient temperature. After brief mixing, 500 mL of the
mobile phase was added to 500-mL aliquots of the thawed
vitreous and blood samples. After mixing for 1.0 min, the
samples were filtered (Durapore, 0.2 mm, Millipore) and 100
mL was injected into the column. To reduce experimental
variability, all the samples were measured together in the
same assay.
A standard stock solution was prepared in methanol that
contained 1 mg/mL acyclovir. This solution was added to
drug-free rabbit vitreous and blood to prepare six non-zero
concentrations in the range of 0.25–15.0 mg/mL acyclovir
(0.25, 0.5, 2.0, 5.0, 10.0, and 15.0 mg/mL).
The ocular pharmacokinetic model was developed using
previously described studies as a reference (12,13). All the
data were fit with a single exponent according to Equation
1, and the estimated half-time (t1/2) of acyclovir elimination
was calculated with Equation 2.
C tð Þ~Coexp({kt)
t1=2~0:693=k
where C (mg/mL) and C0 (mg/mL) represent respectively the
acyclovir concentration at any time and at t0, t (day) is the
time after injection, and k (day-1) represents a rate constant.
Electroretinography
To evaluate the effect of acyclovir on retinal function,
electroretinograms (ERGs) were recorded in the 8 animals
that were sacrificed 28 days after injection. ERG recordings
were obtained on days 2, 9, 14, and 28 after intravitreal
injection.
The ERG protocol was based on the international standard
for electroretinography from the International Society for
Clinical Electrophysiology of Vision (ISCEV) (14). The
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animals were dark-adapted for 1 h and anesthetized with a
mixture of ketamine hydrochloride (50 mg/kg) and xylazine
hydrochloride (6.7 mg/kg), and the pupils were dilated
15 min before ERG using a topical application of 0.5%
tropicamide (Mydriacyl; Alcon, Sa˜o Paulo, Brazil). Imme-
diately before the ERG recordings, the eyes were topically
anesthetized with 0.5% proxymetacaine hydrochloride
(Anestalcon; Alcon, Sa˜o Paulo, Brazil).
The ERG responses from both eyes were recorded using a
corneal bipolar contact lens electrode (GoldLens; Doran
Instruments Inc., Littleton, MA). Reference electrodes were
placed in the skin near the lateral canthus of the eyes, and a
ground electrode (model E5; Grass Technologies, West
Warwick, RI) was placed on the ear.
Light stimulation was provided by a Ganzfeld LED
stimulator (Q450 SC Roland-Consult, Germany) and was
controlled by a computerized system (RetiPort, Roland
Consult, Germany).
ERGs were recorded according to a modified ISCEV
protocol (14,15):
1) Dark-adapted ERG: Five stimulus intensities were tested
after dark adaptation: a) 10 flashes were presented at 0.0003
cd.s/m2 with 5-s interflash intervals; b) 6 flashes were
presented at 0.003 cd.s/m2 with 5-s interflash intervals; c)
after 20 s of dark adaptation, 6 flashes were presented at
0.03 cd.s/m2 with an interflash interval of 10 s; d) after
1 min of dark adaptation, 6 flashes were presented at
0.3 cd.s/m2 with an interflash interval of 10 s; and e) after
1 min of dark adaptation, 3 flashes were presented at
3.0 cd.s/m2 with an interflash interval of 15 s.
2) Light-adapted ERG: A 2-min light adaptation was
conducted with a background of 25 cd.s/m2 (white light)
using an average of 6 flashes at 3.0 cd.s/m2 with an
interflash interval of 5 s.
ERG data analysis: The a- and b-wave amplitudes and the
implicit times were measured. The a-wave amplitude was
measured from the baseline to the minimum amplitude
after light stimulus onset. The a-wave time to peak or
implicit time was measured from flash onset to the a-wave
peak. The b-wave amplitude was measured from the a-
wave through the b-wave peak amplitude. Similarly, the b-
wave implicit time corresponded to the time of occurrence
of its peak amplitude (14).
The correlation between the dark-adapted b-wave ampli-
tude and the stimulus luminance was modeled using the
Naka-Rushton function. The following three parameters
were obtained: the b-wave saturating amplitude (Vmax); the
dark-adapted sensitivity, which was defined as the intensity
necessary for a response amplitude of 50% of the Vmax (k);
and the exponential of the Naka-Rushton equation (n),
which is related to the slope in the linear phase of the
sigmoid function and represents the homogeneity of the
retinal sensitivity.
Analysis
The statistical analysis was performed using Statistica
software (StatSoft v6.0, Inc., Tulsa, OK, USA,). The assess-
ment of the significant differences among the groups was
performed using the repeated-measures ANOVA test,
which takes into account the strength of the correlations
and provides information regarding the variables. The
Fisher’s Least Significant Differences Test was used to
determine the differences between the group means in the
repeated-measures ANOVA tests.
RESULTS
Clinical findings
No cataracts, anterior chamber cells, vitreous cells, retinal
lesions, or cases of endophthalmitis were detected in the
eyes that were injected with acyclovir or saline at any time
point during the study period.
Acyclovir pharmacokinetics
The HPLC method was validated, and a calibration curve
was obtained. The HPLC sensitivity was 0.1 mg/mL. The
vitreous concentrations of acyclovir over 28 days are
presented in Figure 1. The mean intravitreal concentrations
of acyclovir (mg/mL) were 0.28, 0.09, 0.06, and 0.08 on days
2, 9, 14, and 28 after injection, respectively. The half-life of
acyclovir in the rabbit vitreous could not be estimated
because the drug was quickly eliminated and only a small
amount was detected on the second day after injection.
Acyclovir was not detected in the peripheral blood of any
animal that was tested.
ERG
The representative dark- and light-adapted ERG record-
ings of one animal at different time points are shown in
Figure 2. The eyes that were injected with acyclovir were
compared with the eyes that were injected with saline. In
the dark- and light-adapted states, no significant differences
were found between the means of the a- and b-wave
amplitudes and the implicit times for any time point or light
intensity. The data from the dark-adapted ERG recordings
are shown in Table 1.
The dark- and light-adapted a-wave and b-wave mean
amplitudes were plotted against the log light intensity (VlogI)
using the Naka-Rushton equation. The curves at each time
point were compared to the mean baseline curve. No
significant differences were found for the a-wave or b-wave
amplitudes on days 9, 14, and 28 compared with the baseline.
The data for the b-wave amplitudes are presented in Figure 3.
The Vmax, k, and n values were calculated for the b-wave
amplitudes, and no significant differences were found
between the eyes that were injected with acyclovir and
saline. The b-wave Vmax, k, and n values are presented in
Table 2.
The b-wave to a-wave correlations for the dark-adapted
state (30 cd.s/m2) are shown in Figure 4. No significant
differences were found among the different time points.
Figure 1 - Acyclovir concentrations in the vitreous at different
time points after intravitreal injection.
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Oscillatory potentials could not be detected in any of the
eyes that were studied.
DISCUSSION
Our ERG results suggest that intravitreal injection of
acyclovir 1 mg in 0.1 mL does not cause functional changes
in the retina of New Zealand white rabbits according to
binocular indirect ophthalmoscopy and ERG during a 28-day
follow-up period.
This is the first report of experimental data on the retinal
effects of 1 mg acyclovir injected directly into the vitreous.
The injected dose was estimated based on the dose that was
used for the intravenous injections and on a dose-escalating
study (Damico FM et al., unpublished), which demonstrated
that 1 mg acyclovir injected into the vitreous does not cause
morphological changes in the rabbit retina, according to
light microscopy.
ERG is a useful tool that is commonly employed to
monitor retinal toxicity (16). In addition to the determina-
tion of a- and b-wave amplitudes and implicit times in light-
and dark-adapted states, many correlations and other
parameters can be analyzed. The analysis of the correlation
between b-wave amplitude and light intensity at different
Figure 2 - Representative ERG recordings of the eyes of one animal at different time points [dark-adapted (30 cd.s/m2) and light-
adapted (3 cd.s/m2) states].
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time points offers an estimate of the functional integrity of
the retina. Different ERG components are related to
different retinal structures. The cornea negative a-wave
reflects the function of the photoreceptors; the b-wave
reflects the function of bipolar and Mueller cells; and the
oscillatory potentials reflect the activity of the inner retina
(17). Moreover, the b-wave to a-wave amplitude ratio is an
index of post-receptoral function that represents the effect of
a given stimulus in the inner and outer retina (18).
In this study, ERG recordings were obtained at baseline
and at 3 different time points after intravitreal injection of
acyclovir into the study eye and saline into the contralateral
eye. ERG parameters are influenced by many factors, such
as pupil size, dark adaptation time, electrode, stimulus
intensity, age, breed, anesthetic drugs, and body tempera-
ture (19,20); however, it is difficult to control for these
factors. Our results presented low variability (Table 1),
which reflects the high quality of the ERG technique.
There were no significant differences between the a- and
b-wave amplitude values and the implicit time values,
which suggests that the inner and outer retina were not
functionally impaired by the dose of acyclovir that was used
in this study. In addition, the b-wave to a-wave ratios were
not different between the eyes that were injected with
acyclovir and saline, which suggests that the 1-mg dose of
acyclovir does not cause the deterioration of retinal
function. However, full-field ERG is a mass electrical
response of the retina to light stimulation, and acyclovir
may cause focal damage to the retina that may not be
detected by testing. Intravitreal injections of bevacizumab
do not induce signs of toxicity in the rabbit retina according
to ERG (21,22). However, inflammatory cells and signs of
apoptosis in the photoreceptors were observed using
transmission electron microscopy in these studies. Similar
findings were obtained for a high-dose intravitreal injection
of moxifloxacin (23).
Experimental studies in the 1980s evaluated the retinal
toxicity of acyclovir after intravitreal injection (24-26) and
demonstrated that doses of up to 450 mg/0.1 mL do not
Table 1 - a- and b-wave amplitudes and implicit time means at different light intensities and time points (dark-adapted
state). Eight animals were included at each time point. SD= standard deviation; N.R. =not registered.
Light
energy a-wave b-wave
Amplitude (mV) Implicit time (ms) Amplitude (mV) Implicit time (ms)
(cd.s/m2) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Acyclovir Saline Acyclovir Saline Acyclovir Saline Acyclovir Saline
Baseline
0.003 N.R. N.R. N.R. N.R. 23 (8) 21 (7) 82 (3) 82 (19)
0.03 N.R. N.R. N.R. N.R. 108 (58) 89 (14) 83 (6) 85 (4)
0.3 N.R. N.R. N.R. N.R. 130 (32) 110 (21) 68 (2) 74 (4)
3 -72 (43) -75 (28) 45 (1) 45 (4) 210 (56) 189 (34) 67 (1) 70 (12)
30 -143 (24) -132 (42) 42 (0) 36 (2) 259 (47) 232 (55) 66 (1) 72 (13)
9 days
0.003 N.R. N.R. N.R. N.R. 16 (9) 11 (4) 73 (9) 74 (9)
0.03 N.R. N.R. N.R. N.R. 119 (42) 119 (18) 80 (4) 83 (6)
0.3 N.R. N.R. N.R. N.R. 134 (37) 147 (25) 68 (1) 78 (4)
3 -58 (34) -72 (13) 45 (1) 47 (6) 196 (42) 209 (37) 67 (3) 59 (4)
30 -127 (24) -137 (39) 42 (0) 45 (2) 260 (53) 281 (59) 72 (8) 54 (15)
14 days
0.003 N.R. N.R. N.R. N.R. 11 (8) 11 (3) 89 (0) 84 (10)
0.03 N.R. N.R. N.R. N.R. 117 (59) 157 (39) 84 (4) 72 (5)
0.3 N.R. N.R. N.R. N.R. 195 (94) 254 (53) 81 (11) 72 (5)
3 -74 (34) -65 (42) 47 (1) 46 (5) 231 (105) 261 (47) 66 (1) 67 (4)
30 -118 (51) -127 (44) 43 (1) 42 (2) 264 (109) 303 (63) 66 (2) 63 (6)
28 days
0.003 N.R. N.R. N.R. N.R. 23 (19) 17 (4) 77 (21) 87 (16)
0.03 N.R. N.R. N.R. N.R. 173 (65) 190 (73) 80 (5) 90 (6)
0.3 N.R. N.R. N.R. N.R. 220 (94) 178 (49) 75 (11) 78 (5)
3 -80 (28) -77 (38) 46 (2) 44 (5) 305 (102) 243 (64) 79 (13) 73 (5)
30 -116 (30) -131 (42) 42 (1) 40 (2) 347 (85) 275 (101) 77 (11) 75 (9)
Figure 3 - Response versus log light intensity (VlogI) curve of the
eyes that were injected with acyclovir and saline solution. The
gray area represents the mean ¡1 standard deviation of the b-
wave amplitude of the eyes that were injected with saline
solution.
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cause retinal toxicity; however, the same animals were not
used as controls. In contrast, in the present study the
contralateral eye of the same animal was used as control.
The use of different animals as controls may not be adequate
because of the high inter-animal variability in ERG para-
meters. In addition, the ERG methods and data were not
well described in the previous studies, which makes compa-
risons with our results difficult.
The pharmacokinetic study revealed that systemic acy-
clovir absorption after intravitreal injection may not be
significant because the drug was not detected in the
peripheral blood of any animal.
This is the first report on the vitreous half-life of acyclovir.
HPLC indicated a rapid decay in the concentration of
acyclovir in the vitreous during the first two days after
intravitreal injection, after which the acyclovir was main-
tained at low levels from day 9 on. Acyclovir is a Bio-
pharmaceutics Classification System Class III compound and
is highly water-soluble with low permeability and a low
molecular mass. In addition, the systemic half-life of acyclovir
after oral intake has been observed to vary from 2.5 to 3 h
(27,28). In rabbits, the systemic half-life is even lower, varying
from 1 to 2 h (29). These results suggest that acyclovir may
present a short half-life in the vitreous, which may explain the
rapid clearance from the vitreous that was observed in this
study. However, acyclovir would not be detected if it were
bound to serum proteins (30). This hypothesis was not tested
in the present study. In this study, the determination of the
vitreous half-life of acyclovir was not possible because of the
intervals that were chosen for sample collection. However,
our results suggest that the vitreous half-life of acyclovir may
be very short, such as less than 48 h.
This study has several limitations. The relatively low
number of animals that underwent ERG assessment (eight
animals) may mask differences between the eyes that were
injected with acyclovir and saline. However, our results had
low variability, which suggests that they are reliable. In
addition, acyclovir is highly soluble in water and vitreous
clearance is likely to be very short. ERG was recorded at
baseline and on day 9, when a small amount of acyclovir
Table 2 - b-wave amplitude parameters obtained from the response versus log light intensity (VlogI) curve using the
Naka-Rushton equation (dark-adapted state).
Time point b-wave amplitude
Vmax k n
Acyclovir Saline p-value Acyclovir Saline p-value Acyclovir Saline p-value
Baseline 2.492 2.340 0.299 0.0082 0.0019 0.200 0.7367 0.4743 0.121
7 days 2.335 2.333 0.971 0.0030 0.0040 0.081 0.9052 0.9639 0.750
14 days 2.341 2.443 0.342 0.0052 0.0041 0.532 0.9984 1.1895 0.325
28 days 2.455 2.352 0.138 0.0045 0.0030 0.338 1.0167 2.1552 0.258
Figure 4 - b-wave to a-wave (dark-adapted state, 30 cd.s/m2) correlations between the eyes that were injected with acyclovir and saline
at different time points. Each point represents the a- and b-wave amplitudes from one eye.
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was present in the vitreous. Thus, acyclovir may have
caused functional retinal damage within the first hours or
days after intravitreal injection that was not detectable 9
days after injection. Therefore, extensive functional retinal
recovery may have occurred. Finally, this is an experimental
study and the limitations of the rabbit model include
differences in retinal vascularization and eye volume when
compared with the human eye. For these reasons, the results
may not fully represent the effects in human eyes.
In conclusion, this pharmacokinetic study suggests that
the vitreous half-life of acyclovir is very short, and the
clinical and electrophysiological findings suggest that
intravitreal delivery of acyclovir 1 mg in 0.1 mL is safe
and well tolerated by rabbit retina. Before intravitreal
acyclovir can be used as an adjuvant therapy during early
ARN to compensate for the delay in systemic acyclovir
reaching therapeutic levels in the retina, additional studies
are necessary to determine the precise vitreous half-life of
acyclovir, and dose-escalating studies are necessary to
determine safe doses for intravitreal injection.
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